CoChat
Sign Up
Cited by 55

Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury

Lin, Christine, Khetani, Salman R.·2016·BioMed Research International
DOI 10.1155/2016/1829148PMC PMC5048025
Open this paper in CoChat — free account

Abstract

Drug-induced liver injury (DILI) is a major cause of drug attrition. Testing drugs on human liver models is essential to mitigate the risk of clinical DILI since animal studies do not always suffice due to species-specific differences in liver pathways. While primary human hepatocytes (PHHs) can be cultured on extracellular matrix proteins, a rapid decline in functions leads to low sensitivity (<50%) in DILI prediction. Semiconductor-driven engineering tools now allow precise control over the hepatocyte microenvironment to enhance and stabilize phenotypic functions. The latest platforms coculture PHHs with stromal cells to achieve hepatic stability and enable crosstalk between the various liver cell types towards capturing complex cellular mechanisms in DILI. The recent introduction of induced pluripotent stem cell-derived human hepatocyte-like cells can potentially allow a better understanding of interindividual differences in idiosyncratic DILI. Liver models are also being coupled to other tissue models via microfluidic perfusion to study the intertissue crosstalk upon drug exposure as in a live organism. Here, we review the major advances being made in the engineering of liver models and readouts as they pertain to DILI investigations. We anticipate that engineered human liver models will reduce drug attrition, animal usage, and cases of DILI in humans.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2016/1829148

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 107

  1. [2]Abboud G. Kaplowitz N. Drug-induced liver injury Drug Safety 2007 30 4 277 294 10.2165/00002018-200730040-00001 2-s2.0-34247259568 17408305 · DOI
  2. [4]Guillouzo A. Liver cell models in in vitro toxicology Environmental Health Perspectives 1998 106 2 511 532 10.1289/ehp.98106511 2-s2.0-0031832805 9599700 PMC1533385 · DOI
  3. [5]Yum K. Hong S. G. Healy K. E. Lee L. P. Physiologically relevant organs on chips Biotechnology Journal 2014 9 1 16 27 10.1002/biot.201300187 2-s2.0-84891930814 24357624 PMC4481737 · DOI
  4. [7]Donato M. T. Lahoz A. Castell J. V. Gómez-Lechón M. J. Cell lines: a tool for in vitro drug metabolism studies Current Drug Metabolism 2008 9 1 1 11 10.2174/138920008783331086 2-s2.0-38849184046 18220566 · DOI
  5. [8]Anthérieu S. Rogue A. Fromenty B. Guillouzo A. Robin M.-A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in heparg cells Hepatology 2011 53 6 1895 1905 10.1002/hep.24290 2-s2.0-79957474305 21391224 · DOI
  6. [9]Sharanek A. Burban A. Burbank M. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs Scientific Reports 2016 6 24709 10.1038/srep24709 PMC4867683 27169750 · DOI
  7. [10]Wilkening S. Stahl F. Bader A. Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties Drug Metabolism and Disposition 2003 31 8 1035 1042 10.1124/dmd.31.8.1035 2-s2.0-0042904900 12867492 · DOI · Paper page
  8. [11]Gerets H. H. J. Tilmant K. Gerin B. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins Cell Biology and Toxicology 2012 28 2 69 87 10.1007/s10565-011-9208-4 2-s2.0-84859163249 22258563 PMC3303072 · DOI · Paper page
  9. [12]Xu J. J. Henstock P. V. Dunn M. C. Smith A. R. Chabot J. R. de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury Toxicological Sciences 2008 105 1 97 105 10.1093/toxsci/kfn109 2-s2.0-49249103327 18524759 · DOI
  10. [13]Bi Y.-A. Kazolias D. Duignan D. B. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport Drug Metabolism and Disposition 2006 34 9 1658 1665 10.1124/dmd.105.009118 2-s2.0-33747841593 16782767 · DOI · Paper page
  11. [14]Khetani S. R. Bhatia S. N. Microscale culture of human liver cells for drug development Nature Biotechnology 2008 26 1 120 126 10.1038/nbt1361 2-s2.0-38049011979 18026090 · DOI · Paper page
  12. [15]Bhatia S. N. Balis U. J. Yarmush M. L. Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells The FASEB Journal 1999 13 14 1883 1900 2-s2.0-0032721936 10544172
  13. [16]Qin D. Xia Y. Whitesides G. M. Soft lithography for micro- and nanoscale patterning Nature Protocols 2010 5 3 491 502 10.1038/nprot.2009.234 2-s2.0-77749333437 20203666 · DOI
  14. [17]Nguyen T. V. Ukairo O. Khetani S. R. Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters Drug Metabolism and Disposition 2015 43 5 774 785 10.1124/dmd.114.061317 2-s2.0-84952328157 25739975 · DOI
  15. [18]Khetani S. R. Kanchagar C. Ukairo O. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans Toxicological Sciences 2013 132 1 107 117 10.1093/toxsci/kfs326 2-s2.0-84876475743 23152190 · DOI
  16. [19]Chen M. Zhang J. Wang Y. The liver toxicity knowledge base: a systems approach to a complex end point Clinical Pharmacology and Therapeutics 2013 93 5 409 412 10.1038/clpt.2013.16 2-s2.0-84876665555 23486446 · DOI
  17. [22]Manning F. J. Swartz M. Review of the Fialuridine (FIAU) Clinical Trials 1995 Institute of Medicine (US) Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials 25121268
  18. [23]Zinchenko Y. S. Schrum L. W. Clemens M. Coger R. N. Hepatocyte and Kupffer cells co-cultured on micropatterned surfaces to optimize hepatocyte function Tissue Engineering 2006 12 4 751 761 10.1089/ten.2006.12.751 2-s2.0-33646703323 16674289 · DOI
  19. [24]Cho C. H. Park J. Tilles A. W. Berthiaume F. Toner M. Yarmush M. L. Layered patterning of hepatocytes in co-culture systems using microfabricated stencils BioTechniques 2010 48 1 47 52 10.2144/000113317 2-s2.0-77449160201 20078427 PMC3147300 · DOI
  20. [25]Liu Y. Wei J. Lu J. Lei D. Yan S. Li X. Micropatterned coculture of hepatocytes on electrospun fibers as a potential in vitro model for predictive drug metabolism Materials Science and Engineering: C 2016 63 475 484 10.1016/j.msec.2016.03.025 27040241 · DOI
  21. [26]Gerbal-Chaloin S. Funakoshi N. Caillaud A. Gondeau C. Champon B. Si-Tayeb K. Human induced pluripotent stem cells in hepatology: beyond the proof of concept American Journal of Pathology 2014 184 2 332 347 10.1016/j.ajpath.2013.09.026 2-s2.0-84892173562 24269594 · DOI
  22. [27]Ware B. R. Berger D. R. Khetani S. R. Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes Toxicological Sciences 2015 145 2 252 262 10.1093/toxsci/kfv048 2-s2.0-84928328255 25716675 · DOI
  23. [28]Ramaiahgari S. C. den Braver M. W. Herpers B. A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies Archives of Toxicology 2014 88 5 1083 1095 10.1007/s00204-014-1215-9 2-s2.0-84901339650 24599296 · DOI
  24. [29]Gunness P. Mueller D. Shevchenko V. Heinzle E. Ingelman-Sundberg M. Noor F. 3D organotypic cultures of human heparg cells: a tool for in vitro toxicity studies Toxicological Sciences 2013 133 1 67 78 10.1093/toxsci/kft021 2-s2.0-84876802415 23377618 · DOI · Paper page
  25. [30]Mueller D. Krämer L. Hoffmann E. Klein S. Noor F. 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies Toxicology in Vitro 2014 28 1 104 112 10.1016/j.tiv.2013.06.024 2-s2.0-84888290491 23850736 · DOI
  26. [31]Kostadinova R. Boess F. Applegate D. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity Toxicology and Applied Pharmacology 2013 268 1 1 16 10.1016/j.taap.2013.01.012 2-s2.0-84873905748 23352505 · DOI · Paper page
  27. [32]Gieseck R. L. III Hannan N. R. F. Bort R. Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture PLoS ONE 2014 9 1 e86372 10.1371/journal.pone.0086372 2-s2.0-84899644210 PMC3899231 24466060 · DOI
  28. [33]Rebelo S. P. Costa R. Silva M. M. Marcelino P. Brito C. Alves P. M. Three-dimensional co-culture of human hepatocytes and mesenchymal stem cells: improved functionality in long-term bioreactor cultures Journal of Tissue Engineering and Regenerative Medicine 2015 10.1002/term.2099 2-s2.0-84949293968 26511086 · DOI
  29. [34]Bell C. C. Hendriks D. F. G. Moro S. M. L. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease Scientific Reports 2016 6, article 25187 10.1038/srep25187 PMC4855186 27143246 · DOI · Paper page
  30. [35]Tong W. H. Fang Y. Yan J. Constrained spheroids for prolonged hepatocyte culture Biomaterials 2016 80 106 120 10.1016/j.biomaterials.2015.11.036 2-s2.0-84951776310 26708088 · DOI
  31. [37]Miyamoto Y. Ikeuchi M. Noguchi H. Yagi T. Hayashi S. Spheroid formation and evaluation of hepatic cells in a three-dimensional culture device Cell Medicine 2015 8 1 47 56 10.3727/215517915x689056 26858908 PMC4733911 · DOI
  32. [38]Takayama K. Kawabata K. Nagamoto Y. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing Biomaterials 2013 34 7 1781 1789 10.1016/j.biomaterials.2012.11.029 2-s2.0-84871080430 23228427 · DOI
  33. [39]Ma X. Qu X. Zhu W. Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting Proceedings of the National Academy of Sciences of the United States of America 2016 113 8 2206 2211 10.1073/pnas.1524510113 26858399 PMC4776497 · DOI
  34. [40]Li C. Y. Stevens K. R. Schwartz R. E. Alejandro B. S. Huang J. H. Bhatia S. N. Micropatterned cell-cell interactions enable functional encapsulation of primary hepatocytes in hydrogel microtissues Tissue Engineering Part A 2014 20 15-16 2200 2212 10.1089/ten.tea.2013.0667 2-s2.0-84902097724 24498910 PMC4137334 · DOI · Paper page
  35. [41]Lutolf M. P. Hubbell J. A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering Nature Biotechnology 2005 23 1 47 55 10.1038/nbt1055 2-s2.0-19644367664 15637621 · DOI · Paper page
  36. [42]Tasnim F. Toh Y. Qu Y. Functionally enhanced human stem cell derived hepatocytes in galactosylated cellulosic sponges for hepatotoxicity testing Molecular Pharmaceutics 2016 13 6 1947 1957 10.1021/acs.molpharmaceut.6b00119 27157693 · DOI
  37. [43]Jungermann K. Kietzmann T. Zonation of parenchymal and nonparenchymal metabolism in liver Annual Review of Nutrition 1996 16 179 203 10.1146/annurev.nu.16.070196.001143 2-s2.0-0029800090 8839925 · DOI · Paper page
  38. [44]Allen J. W. Bhatia S. N. Formation of steady-state oxygen gradients in vitro: application to liver zonation Biotechnology and Bioengineering 2003 82 3 253 262 10.1002/bit.10569 2-s2.0-0037420747 12599251 · DOI · Paper page
  39. [45]Allen J. W. Khetani S. R. Bhatia S. N. In vitro zonation and toxicity in a hepatocyte bioreactor Toxicological Sciences 2005 84 1 110 119 10.1093/toxsci/kfi052 2-s2.0-14844320510 15590888 · DOI
  40. [46]Novik E. Maguire T. J. Chao P. Cheng K. C. Yarmush M. L. A microfluidic hepatic coculture platform for cell-based drug metabolism studies Biochemical Pharmacology 2010 79 7 1036 1044 10.1016/j.bcp.2009.11.010 2-s2.0-77449119885 19925779 PMC3136813 · DOI
  41. [47]Sivaraman A. Leach J. K. Townsend S. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction Current Drug Metabolism 2005 6 6 569 591 10.2174/138920005774832632 2-s2.0-27944442381 16379670 · DOI
  42. [48]Esch M. B. Prot J.-M. Wang Y. I. Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow Lab on a Chip 2015 15 10 2269 2277 10.1039/c5lc00237k 2-s2.0-84928957146 25857666 PMC4422761 · DOI · Paper page
  43. [49]Lee P. J. Hung P. J. Lee L. P. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture Biotechnology and Bioengineering 2007 97 5 1340 1346 10.1002/bit.21360 2-s2.0-34547581758 17286266 · DOI
  44. [50]Miller P. G. Shuler M. L. Design and demonstration of a pumpless 14 compartment microphysiological system Biotechnology and Bioengineering 2016 113 10 2213 2227 10.1002/bit.25989 27070809 · DOI
  45. [51]Kobayashi A. Yamakoshi K. Yajima Y. Utoh R. Yamada M. Seki M. Preparation of stripe-patterned heterogeneous hydrogel sheets using microfluidic devices for high-density coculture of hepatocytes and fibroblasts Journal of Bioscience and Bioengineering 2013 116 6 761 767 10.1016/j.jbiosc.2013.05.034 2-s2.0-84886387986 23845912 · DOI
  46. [52]Skardal A. Devarasetty M. Soker S. Hall A. R. In situ patterned micro 3D liver constructs for parallel toxicology testing in a fluidic device Biofabrication 2015 7 3 031001 10.1088/1758-5090/7/3/031001 2-s2.0-84945207367 PMC5704969 26355538 · DOI
  47. [53]Ma C. Zhao L. Zhou E.-M. Xu J. Shen S. Wang J. On-chip construction of liver lobule-like microtissue and its application for adverse drug reaction assay Analytical Chemistry 2016 88 3 1719 1727 10.1021/acs.analchem.5b03869 2-s2.0-84957603856 26743823 · DOI · Paper page
  48. [55]Bavli D. Prill S. Ezra E. Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction Proceedings of the National Academy of Sciences of the United States of America 2016 113 16 E2231 E2240 10.1073/pnas.1522556113 27044092 PMC4843487 · DOI
  49. [56]Rennert K. Steinborn S. Gröger M. A microfluidically perfused three dimensional human liver model Biomaterials 2015 71 119 131 17038 10.1016/j.biomaterials.2015.08.043 2-s2.0-84941560577 26322723 · DOI
  50. [57]Vernetti L. A. Senutovitch N. Boltz R. A human liver microphysiology platform for investigating physiology, drug safety, and disease models Experimental Biology and Medicine 2016 241 1 101 114 10.1177/1535370215592121 2-s2.0-84954229680 26202373 PMC4723301 · DOI
  51. [58]Viravaidya K. Sin A. Shuler M. L. Development of a microscale cell culture analog to probe naphthalene toxicity Biotechnology Progress 2004 20 1 316 323 10.1021/bp0341996 2-s2.0-1142305959 14763858 · DOI
  52. [59]Choucha-Snouber L. Aninat C. Grsicom L. Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip Biotechnology and Bioengineering 2013 110 2 597 608 10.1002/bit.24707 2-s2.0-84871719607 22887128 · DOI
  53. [60]Materne E.-M. Ramme A. P. Terrasso A. P. A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing Journal of Biotechnology 2015 205 36 46 10.1016/j.jbiotec.2015.02.002 2-s2.0-84930957041 25678136 · DOI
  54. [63]Materne E.-M. Maschmeyer I. Lorenz A. K. The multi-organ chip—a microfluidic platform for long-term multi-tissue coculture Journal of Visualized Experiments 2015 98 e52526 10.3791/52526 2-s2.0-84941254163 PMC4541596 25992921 · DOI
  55. [64]Sung J. H. Kam C. Shuler M. L. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip Lab on a Chip—Miniaturisation for Chemistry and Biology 2010 10 4 446 455 10.1039/b917763a 2-s2.0-75749153235 20126684 · DOI
  56. [66]Oleaga C. Bernabini C. Smith A. S. T. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs Scientific Reports 2016 6 20030 10.1038/srep20030 2-s2.0-84957586265 PMC4738272 26837601 · DOI · Paper page
  57. [67]Olinga P. Schuppan D. Precision-cut liver slices: a tool to model the liver ex vivo Journal of Hepatology 2013 58 6 1252 1253 10.1016/j.jhep.2013.01.009 2-s2.0-84877920627 23336979 · DOI
  58. [68]Van de Bovenkamp M. Groothuis G. M. M. Meijer D. K. F. Olinga P. Liver fibrosis in vitro: cell culture models and precision-cut liver slices Toxicology in Vitro 2007 21 4 545 557 10.1016/j.tiv.2006.12.009 2-s2.0-34047259551 17289342 · DOI
  59. [69]van Midwoud P. M. Merema M. T. Verweij N. Groothuis G. M. M. Verpoorte E. Hydrogel embedding of precision-cut liver slices in a microfluidic device improves drug metabolic activity Biotechnology and Bioengineering 2011 108 6 1404 1412 10.1002/bit.23053 2-s2.0-79954570688 21274846 · DOI
  60. [70]van Midwoud P. M. Merema M. T. Verpoorte E. Groothuis G. M. M. Microfluidics enables small-scale tissue-based drug metabolism studies with scarce human tissue Journal of Laboratory Automation 2011 16 6 468 476 10.1016/j.jala.2011.07.003 2-s2.0-82855161342 22093304 · DOI
  61. [71]Yuet M. K. Zhang J. Zhou S. Novel intra-tissue perfusion system for culturing thick liver tissue Tissue Engineering 2007 13 9 2345 2356 10.1089/ten.2007.0040 2-s2.0-34548659070 17708717 · DOI
  62. [72]Schumacher K. Khong Y.-M. Chang S. Ni J. Sun W. Yu H. Perfusion culture improves the maintenance of cultured liver tissue slices Tissue Engineering 2007 13 1 197 205 10.1089/ten.2006.0046 2-s2.0-33846570333 17518593 · DOI
  63. [73]Yoshizato K. Tateno C. A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next? Expert Opinion on Drug Metabolism and Toxicology 2013 9 11 1419 1435 10.1517/17425255.2013.826649 2-s2.0-84886032103 23978259 · DOI
  64. [74]Strom S. C. Davila J. Grompe M. Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity Methods in Molecular Biology 2010 640 491 509 10.1007/978-1-60761-688-7_27 2-s2.0-78049374383 20645070 PMC3136240 · DOI
  65. [75]Sanoh S. Horiguchi A. Sugihara K. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver Drug Metabolism and Disposition 2012 40 2 322 328 10.1124/dmd.111.040923 2-s2.0-84855997102 22048522 · DOI
  66. [76]Sanoh S. Ohta S. Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics Biopharmaceutics and Drug Disposition 2014 35 2 71 86 10.1002/bdd.1864 2-s2.0-84896692068 24114658 · DOI
  67. [77]Yamada T. Okuda Y. Kushida M. Human hepatocytes support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogen sodium phenobarbital in an in vivo study using a chimeric mouse with humanized liver Toxicological Sciences 2014 142 1 137 157 10.1093/toxsci/kfu173 2-s2.0-84931054243 25145657 · DOI
  68. [78]Xu D. Nishimura T. Nishimura S. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing PLoS Medicine 2014 11 4 e1001628 10.1371/journal.pmed.1001628 2-s2.0-84900460907 PMC3988005 24736310 · DOI
  69. [79]Xu D. Wu M. Nishimura S. Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity Journal of Pharmacology and Experimental Therapeutics 2015 352 2 274 280 10.1124/jpet.114.220798 2-s2.0-84919771983 25424997 PMC4293443 · DOI
  70. [80]Kakuni M. Morita M. Matsuo K. Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury Toxicology Letters 2012 214 1 9 18 10.1016/j.toxlet.2012.08.001 2-s2.0-84865480870 22902350 · DOI
  71. [81]Akkina R. Human immune responses and potential for vaccine assessment in humanized mice Current Opinion in Immunology 2013 25 3 403 409 10.1016/j.coi.2013.03.009 2-s2.0-84879200744 23628166 PMC3894824 · DOI
  72. [82]Wilson E. M. Bial J. Tarlow B. Extensive double humanization of both liver and hematopoiesis in FRGN mice Stem Cell Research 2014 13 3 404 412 10.1016/j.scr.2014.08.006 2-s2.0-84908027919 25310256 PMC7275629 · DOI
  73. [83]Bility M. T. Zhang L. Washburn M. L. Curtis T. A. Kovalev G. I. Su L. Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis Nature Protocols 2012 7 9 1608 1617 10.1038/nprot.2012.083 2-s2.0-84866130619 22899330 PMC3979325 · DOI
  74. [84]Chen A. A. Thomas D. K. Ong L. L. Schwartz R. E. Golub T. R. Bhatia S. N. Humanized mice with ectopic artificial liver tissues Proceedings of the National Academy of Sciences of the United States of America 2011 108 29 11842 11847 10.1073/pnas.1101791108 2-s2.0-79961066293 21746904 PMC3142004 · DOI
  75. [85]Ohashi K. Marion P. L. Nakai H. Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis delta viruses Nature Medicine 2000 6 3 327 331 10.1038/73187 2-s2.0-0034018854 10700236 · DOI
  76. [86]Persson M. Løye A. F. Jacquet M. High-content analysis/screening for predictive toxicology: application to hepatotoxicity and genotoxicity Basic and Clinical Pharmacology and Toxicology 2014 115 1 18 23 10.1111/bcpt.12200 2-s2.0-84902074103 24461077 · DOI
  77. [87]Wink S. Hiemstra S. Huppelschoten S. Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment Chemical Research in Toxicology 2014 27 3 338 355 10.1021/tx4004038 2-s2.0-84896355899 24450961 · DOI
  78. [88]Tolosa L. Gómez-Lechón M. J. Donato M. T. High-content screening technology for studying drug-induced hepatotoxicity in cell models Archives of Toxicology 2015 89 7 1007 1022 10.1007/s00204-015-1503-z 2-s2.0-84930925098 25787152 · DOI
  79. [89]O'Brien P. J. Irwin W. Diaz D. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening Archives of Toxicology 2006 80 9 580 604 10.1007/s00204-006-0091-3 2-s2.0-33747084103 16598496 · DOI · Paper page
  80. [90]Garside H. Marcoe K. F. Chesnut-Speelman J. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes Toxicology in Vitro 2014 28 2 171 181 10.1016/j.tiv.2013.10.015 2-s2.0-84889586629 24189122 · DOI · Paper page
  81. [91]Trask O. J. Jr. Moore A. LeCluyse E. L. A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis Assay and Drug Development Technologies 2014 12 1 16 27 10.1089/adt.2013.525 2-s2.0-84896715122 24444127 · DOI
  82. [92]Cole S. D. Madren-Whalley J. S. Li A. P. Dorsey R. Salem H. High content analysis of an in vitro model for metabolic toxicity: results with the model toxicants 4-aminophenol and cyclophosphamide Journal of Biomolecular Screening 2014 19 10 1402 1408 10.1177/1087057114550399 2-s2.0-84912010039 25239051 · DOI
  83. [93]Sirenko O. Hesley J. Rusyn I. Cromwell E. F. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells Assay and Drug Development Technologies 2014 12 1 43 54 10.1089/adt.2013.520 2-s2.0-84896696047 24229356 PMC3934660 · DOI
  84. [94]Grimm F. A. Iwata Y. Sirenko O. Bittner M. Rusyn I. High-content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived cardiomyocytes and hepatocytes Assay and Drug Development Technologies 2015 13 9 529 546 10.1089/adt.2015.659 2-s2.0-84948147405 26539751 PMC4652224 · DOI
  85. [95]Pradip A. Steel D. Jacobsson S. High content analysis of human pluripotent stem cell derived hepatocytes reveals drug induced steatosis and phospholipidosis Stem Cells International 2016 2016 14 2475631 10.1155/2016/2475631 2-s2.0-84955472147 PMC4736406 26880940 · DOI
  86. [96]Godoy P. Bolt H. M. Toxicogenomic-based approaches predicting liver toxicity in vitro Archives of Toxicology 2012 86 8 1163 1164 10.1007/s00204-012-0892-5 2-s2.0-84866049813 22707156 · DOI
  87. [97]Zhang M. Chen M. Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? Chemical Research in Toxicology 2012 25 1 122 129 10.1021/tx200320e 2-s2.0-84862932616 22122743 · DOI
  88. [98]Rodrigues R. M. Heymans A. De Boe V. Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems Toxicology Letters 2016 240 1 50 59 10.1016/j.toxlet.2015.10.014 2-s2.0-84946430919 26497421 · DOI
  89. [99]Schug M. Heise T. Bauer A. Primary rat hepatocytes as in vitro system for gene expression studies: comparison of sandwich, Matrigel and 2D cultures Archives of Toxicology 2008 82 12 923 931 10.1007/s00204-008-0375-x 2-s2.0-59849100943 18987846 · DOI
  90. [100]Jiang J. Wolters J. E. J. van Breda S. G. Kleinjans J. C. de Kok T. M. Development of novel tools for the in vitro investigation of drug-induced liver injury Expert Opinion on Drug Metabolism and Toxicology 2015 11 10 1523 1537 10.1517/17425255.2015.1065814 2-s2.0-84941946184 26155718 · DOI
  91. [101]Iruzubieta P. Arias-Loste M. T. Barbier-Torres L. Martinez-Chantar M. L. Crespo J. The need for biomarkers in diagnosis and prognosis of drug-induced liver disease: does metabolomics have any role? BioMed Research International 2015 2015 8 386186 10.1155/2015/386186 2-s2.0-84956906812 PMC4707380 26824035 · DOI
  92. [102]Raies A. B. Bajic V. B. In silico toxicology: computational methods for the prediction of chemical toxicity Wiley Interdisciplinary Reviews: Computational Molecular Science 2016 6 2 147 172 10.1002/wcms.1240 2-s2.0-84953410798 27066112 PMC4785608 · DOI
  93. [103]Zhu X.-W. Sedykh A. Liu S.-S. Hybrid in silico models for drug-induced liver injury using chemical descriptors and in vitro cell-imaging information Journal of Applied Toxicology 2014 34 3 281 288 10.1002/jat.2879 2-s2.0-84892955302 23640866 · DOI
  94. [104]Mulliner D. Schmidt F. Stolte M. Spirkl H.-P. Czich A. Amberg A. Computational models for human and animal hepatotoxicity with a global application scope Chemical Research in Toxicology 2016 29 5 757 767 10.1021/acs.chemrestox.5b00465 26914516 · DOI
  95. [105]Vedani A. Dobler M. Hu Z. Smieško M. OpenVirtualToxLab—a platform for generating and exchanging in silico toxicity data Toxicology Letters 2015 232 2 519 532 10.1016/j.toxlet.2014.09.004 2-s2.0-84918807466 25240273 · DOI
  96. [106]Kleinstreuer N. C. Yang J. Berg E. L. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms Nature Biotechnology 2014 32 6 583 591 10.1038/nbt.2914 2-s2.0-84902166194 24837663 · DOI · Paper page
  97. [108]Howell B. A. Yang Y. Kumar R. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsymTM: a mechanistic, mathematical model of DILI Journal of Pharmacokinetics and Pharmacodynamics 2012 39 5 527 541 10.1007/s10928-012-9266-0 2-s2.0-84870395485 22875368 · DOI
  98. [109]Subramanian K. Raghavan S. Bhat A. R. A systems biology based integrative framework to enhance the predictivity of in vitro methods for drug-induced liver injury Expert Opinion on Drug Safety 2008 7 6 647 662 10.1517/14740330802501211 2-s2.0-57049095489 18983213 · DOI
  99. [110]Shardlow C. E. Generaux G. T. Patel A. H. Tai G. Tran T. Bloomer J. C. Impact of physiologically based pharmacokinetic modeling and simulation in drug development Drug Metabolism and Disposition 2013 41 12 1194 2003 10.1124/dmd.113.052803 2-s2.0-84888624560 24009310 · DOI
  100. [111]Zurlinden T. J. Reisfeld B. Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach European Journal of Drug Metabolism and Pharmacokinetics 2016 41 3 267 280 10.1007/s13318-015-0253-x 2-s2.0-84921947279 25636597 · DOI
  101. [112]LeCluyse E. L. Witek R. P. Andersen M. E. Powers M. J. Organotypic liver culture models: meeting current challenges in toxicity testing Critical Reviews in Toxicology 2012 42 6 501 548 10.3109/10408444.2012.682115 2-s2.0-84862181007 22582993 PMC3423873 · DOI · Paper page
  102. [113]Esch M. B. King T. L. Shuler M. L. The role of body-on-a-chip devices in drug and toxicity studies Annual Review of Biomedical Engineering 2011 13 1 55 72 10.1146/annurev-bioeng-071910-124629 2-s2.0-79960527448 21513459 · DOI
  103. [114]Rawlins M. D. Cutting the cost of drug development? Nature Reviews Drug Discovery 2004 3 4 360 364 10.1038/nrd1347 2-s2.0-4544321119 15060531 · DOI
  104. [115]Kaitin K. I. Deconstructing the drug development process: the new face of innovation Clinical Pharmacology and Therapeutics 2010 87 3 356 361 10.1038/clpt.2009.293 2-s2.0-77149134011 20130565 PMC2953249 · DOI
  105. [116]Berger D. R. Ware B. R. Davidson M. D. Allsup S. R. Khetani S. R. Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro Hepatology 2015 61 4 1370 1381 10.1002/hep.27621 2-s2.0-84925307610 25421237 · DOI
  106. [117]Lin C. Shi J. Moore A. Khetani S. R. Prediction of drug clearance and drug-drug interactions in microscale cultures of human hepatocytes Drug Metabolism and Disposition 2016 44 1 127 136 10.1124/dmd.115.066027 2-s2.0-84958160549 26452722 · DOI
  107. [118]Xu D. Peltz G. Can humanized mice predict drug ‘behavior’ in humans? Annual Review of Pharmacology and Toxicology 2016 56 323 338 10.1146/annurev-pharmtox-010715-103644 2-s2.0-84954111235 26514208 · DOI

Cited by

Sorted by citations

Authors
Lin, C., & Khetani, S. R.
Affiliations
  • School of Biomedical Engineering, Colorado State University, Fort Collins, CO 80523, USA
  • Department of Bioengineering, University of Illinois at Chicago, Chicago, IL 60607, USA
ORCID
Khetani, Salman R.
Venue
BioMed Research International
Publisher
Wiley
Published
2016
Volume
2016
Pages
1-20
ISSN
  • 2314-6133
  • 2314-6141
DOI
10.1155/2016/1829148
PMC
PMC5048025
Cited by
55
References
10
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)
Funders
University of Illinois at Chicago

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review